Significant Revenue Growth
Total revenue grew by 21% in Q3 and by 19% year-to-date, with core EPS increasing by 11%.
Upgrade in Full Year Guidance
Full-year guidance upgraded with expectations for both total revenue and core EPS to grow by high teens percentage.
Strong Oncology Performance
Oncology total revenues grew 22% to $16 billion, driven by strong demand in the U.S., Europe, and emerging markets.
Emerging Markets Growth
Emerging markets outside of China showed a standout performance with 30% growth year-to-date.
New Investments in the U.S.
Announced a $3.5 billion investment in the U.S. for manufacturing and R&D to support future growth.
Positive R&D Pipeline Developments
Multiple high-value Phase III readouts with potential new indications and therapies across various areas.